The administration of You Gui Wan (YGW) decoction has been observed to improve vaginal atrophy induced by ovariectomy (OVX) in rats. The aim of the current study was to explore the possible mechanisms underlying this effect. Following OVX, 37 Sprague Dawley female rats were randomly divided into three groups which were orally administered with YGW decoction, saline or estrogen for 11 weeks. In parallel with this, 19 normal and 17 rats with sham‑surgery were used as controls. The effects of these treatments on estrogen receptors (ER) and various angiogenic factors, including vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor‑1 (VEGFR‑1), angiopoietin (Ang)1 and 2 and basic fibroblast growth factor (bFGF) in the vagina were compared using immunohistochemistry or quantitative polymerase chain reaction (qPCR). OVX was found to induce significant vaginal atrophy and decrease the expression of ER and various angiogenic factors when compared with the normal and sham‑surgery animals (all P<0.05). Estrogen replacement and the administration of YGW decoction reversed the vaginal atrophic process. The hormonal replacement and YGW treatment recovered the protein expression of ER‑α and ‑β, VEGF and VEGFR‑1 and the mRNA levels of ER‑α, VEGF, VEGFR‑1, Ang1 and 2, and bFGF when compared with OVX‑rats with saline, normal and sham‑surgery treatments (all P<0.05). Thus, it may be concluded that a possible mechanism underlying the effect of YGW on OVX‑induced vaginal atrophy may be the upregulated expression of ER and various angiogenic factors in the vaginal tissue.
This study aimed to compare the YHLO chemiluminescence immunoassay (CLIA) with the Crithidia luciliae immunofluorescence test (CLIFT) to detect anti-dsDNA antibodies and its correlation with disease activity in systemic lupus erythematosus (SLE).In total, 208 patients diagnosed with SLE, 110 other autoimmune patients, 70 infectious disorders patients, and 105 healthy people were enrolled in this study. Serum samples were tested using CLIA in a YHLO chemiluminescence system and CLIFT.The overall agreement between YHLO CLIA and CLIFT was 76.9% (160/208), with a moderate correlation (kappa = 0.530, p < 0.001). The sensitivity of YHLO CLIA and CLIFT were 58.2% and 55.3%, respectively. The specificity of YHLO CLIA and CLIFT were 95.1% and 99.3%, respectively. The sensitivity of YHLO CLIA was increased to 66.8% with a specificity of 93.6% when the cut-off value was set at 24 IU/mL. Spearman's correlation coefficient between the quantitative results of YHLO CLIA and the titers of CLIFT was 0.59 (p < .01). A significant correlation was found between the anti-dsDNA results detected by YHLO CLIA and the SLE Disease Activity Index 2000 (SLEDAI-2K). Spearman's correlation coefficient between YHLO CLIA and SLEDAI-2K (r = 0.66, p < .01) was higher than that of CLIFT (r = 0.60, p < .01).Good correlation and agreement were found between YHLO CLIA and CLIFT. In addition, there was a significant correlation between YHLO CLIA and the SLE Disease Activity Index, which was superior to that of CLIFT. The YHLO chemiluminescence system is recommended for the assessment of disease activity.
Activated carbon as a carrier,ruthenium chloride as the active precursor preparation for Ru/C catalyst using supercritical CO2 fluid deposition method.The catalytic activity of catalysts were studied by reaction of glucose hydrogenation to sorbitol.The effects of preparation condition for Ru/C catalyst,ie,temperature,the amount of CO2 and the amount of reducing agent KBH4,on activity of the Ru/C catalysts were investigated by orthogonal experiment.Ru/C catalyst samples were investigated by IR and scanning electron microscopy(SEM).The results indicated that properties of the Ru/C catalysts were remarkably affected by temperature.The best process conditions of Ru/C catalyst was that activate carbon was 0.6000 g,RuCl3 was 0.1000 g,the amount of methanol cosolvent was 0.5 mL,the temperature was 60 ℃,CO2 volume was 40 mL,the amount of reducing agent KBH4 was 0.10 g.The best catalytic activity was 28.3 mmol/(min·g) which was 1.89 times than the traditional preparation of the catalyst.RuCl3 combination with the particulate carbon was not a simple physical adhesion,but rather a chemical reaction occurs,the formation of the Ru/C catalyst kept the original surface morphology of carbon particles,ruthenium of distribution was very uniform.
Porcine epidemic diarrhea virus (PEDV) primarily infects suckling piglets and causes severe economic losses to the swine industry. Cytokines, as part of the innate immune response, are important in PEDV infection. The cytokines secreted by cell infection models in vitro might reflect true response to viral infection of target cells in vivo. Vero cells and IPEC-J2 are commonly used as an in vitro model to investigate PEDV infection. However, it is not clear which type of cells is more beneficial to the study of PEDV. In our study, firstly, Vero cells and IPEC-J2 were successfully infected with PEDV virulent strains (HBQY2016) and attenuated vaccine strains (CV777) and were capable of supporting virus replication and progeny release. Moreover, cytokine differences expression by Vero cells and IPEC-J2 cells infected with two PEDV strains were analyzed. Compared with IPEC-J2 cells, only the mRNA levels of TGF-β, MIP-1β and MCP-1 were detected in Vero cells. ELISA assay indicated that compared to the control group, the PEDV-infected group had significantly induced expression levels of IL-1β, MIP-1β, MCP-1, IL-8, and CXCL10 in IPEC-J2 cells, while only secretion level of IL-1β, MIP-1β and IL-8 in Vero cells were higher in PEDV infected group. Finally, cytokines change of piglets infected PEDV-HBQY2016 strains were detected by cDNA microarray, and similar to those of IPEC-J2 cells infected PEDV. Collectively, these data determined that the IPEC-J2 could be more suitable used as a cell model for studying PEDV infection in vitro compared with Vero cells, based on the close approximation of cytokine expression profile to in vivo target cells.
Jacobs R, Pittayapat P, van Steenberghe D, De Mars G, Gijbels F, Van Der Donck A, Li L, Liang X, Van Assche N, Quirynen M, Naert I. A split‐mouth comparative study up to 16 years of two screw‐shaped titanium implant systems. J Clin Periodontol 2010; doi: 10.1111/j.1600‐051X.2010.01626.x. Abstract Introduction: Many studies have dealt with the clinical outcome of oral implants, yet none applied a randomized split‐mouth design for a long‐term follow‐up of similar implant systems. Aim: To evaluate two oral implant systems with different surface characteristics in a randomized split‐mouth design and to radiologically analyse peri‐implant bone level and density over an up to 16‐year period. Materials and Methods: The study comprised clinical and radiographic records of 18 partially edentulous patients treated with both implant types randomly placed in either left or right jaw sides. Outcome was evaluated over time. Results: Clinical and radiographic parameters showed no significant differences over time for both systems. Ten years after implant placement, a significantly increasing peri‐implant bone density was noted, while Periotest values were found to be significantly decreasing. Fifteen years after implant loading, mean bone loss was 0.02 mm (range −1.15 to 1.51; SD 0.45) for Astra Tech ® implants ( n =24) and 0.31 mm (range −0.98 to 2.31; SD 0.69) for Brånemark ® implants ( n =23). Conclusions: The study failed to demonstrate significant differences in the outcome of the peri‐implant bone for two implant systems with different surface characteristics. The marginal bone level around oral implants changed <0.5 mm after 15 years of loading.
To analyze the particularities of diagnosis and treatment of acute cerebral stroke secondary to polycythemia vera (PV).To track and evaluate the clinical parameters, the manifestations of CT/MRI, the data of laboratory examinations, the therapeutic responses and the prognosis of acute cerebral stroke secondary to PV. Twenty-two cases of PV with initial presentation as acute stroke were analyzed.(1) 55.0% of the patients with stroke as the initial presentation of to PV had multiple lacuna infarction. (2) 37.5% of the patients had a temporary symptom aggravation after receiving a therapeutic regimen of blood-letting and chemotherapy, whereas, the stroke symptoms improved and became stable when treated with blood-letting combined with hemodilution and chemotherapy simultaneously. (3) Six cases received homoharringtonine treatment and all of them reached complete remission (CR). However, 3 of them showed ST segment and T-wave changes in electrocardiogram and 2 of them had bone marrow depression. Four cases received arsenic trioxide and obtained CR, but the relapse rate reached 50.0%. Nine cases were treated with hydroxycarbamide and all of them obtained CR.(1) Stroke secondary to PV should be treated with stroke regimen as well as PV therapy, and hydroxycarbamide might have stable benefit and few side effects. (2) Hematocrit assay should be used as a routine item in stroke patients with frequently relapsed.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)